Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rubitecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | GLA | P06280 | 3/20 | 0.78 |
| ▸ | RECQL | P46063 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rubitecan SCHEMBL8640 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL29379605 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL29383355 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL15539941 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL1652417 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL28223445 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL27953003 | 0.98 | ABCC4 (0.95) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL28308474 | 0.96 | ABCC4 (0.93) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL27598505 | 0.94 | ABCC3 (0.89) | ABCC4HTTABCC3ACHEPTGS1 | |
| SCHEMBL25932527 | 0.92 | ABCC4 (0.85) | ABCC4HTTABCC3ACHEPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-103611166-B | 9-nitrocamptothecin-cyclodextrin clathrate and preparation method thereof and the pharmaceutical composition containing this clathrate | Nanjing University of Chinese Medicine (CN) | 2016-02-24 | — | — | CN | disclosed |
| CN-103611166-A | 9-nitrocamptothecin-cyclodextrin inclusion compound and preparation method thereof as well as pharmaceutical composition containing cyclodextrin inclusion compound | UNIV NANJING CHINESE MEDICINE | 2014-03-05 | — | — | CN | disclosed |
| CN-102151248-A | 9-nitrocamptothecin freeze-dried powder injection and preparation method thereof | UNIV FUDAN | 2011-08-17 | — | — | CN | disclosed |
| CN-100393724-C | 20-esterifiable camptothecine derivative and method for making same and pharmaceutical combination and uses | CHINESE ACAD MED SCIENCE (CN) | 2008-06-11 | — | — | CN | disclosed |
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | disclosed |
| CN-1467210-A | 20-esterifiable camptothecine derivative and method for making same and pharmaceutical combination and uses | 中国医学科学院药物研究所 | 2004-01-14 | — | — | CN | disclosed |
| CN-1048296-C | Preparation method of 9-amino camptothecin | PHARMACIA & UPJOHN SPA (IT) | 2000-01-12 | — | — | CN | disclosed |
| CN-1222523-A | Process for preparation of 9-amino camptothecin | PHARMACIA & UPJOHN SPA (IT) | 1999-07-14 | — | — | CN | disclosed |
| CN-1113384-A | Preparation method of 9-amino camptothecin | PHARMACIA SPA (IT) | 1995-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | TOP1 531/4885ABCC4 1731/4885HTT 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.